

WEST

Generate Collection

Print

L2: Entry 11 of 29

File: JPAB

Apr 8, 1997

PUB-NO: JP409094065A

DOCUMENT-IDENTIFIER: JP 09094065 A

TITLE: TEA BEVERAGE CONTAINING AMYLASE INHIBITOR

PUBN-DATE: April 8, 1997

INVENTOR-INFORMATION:

NAME

COUNTRY

KARITA, KANAKO

YOSHIDA, MIEKO

ASSIGNEE-INFORMATION:

NAME

COUNTRY

NISSHIN FLOUR MILLING CO LTD

APPL-NO: JP07273677

APPL-DATE: September 28, 1995

INT-CL (IPC): A23 F 3/16; A23 L 2/70; C12 N 9/99

ABSTRACT:

PROBLEM TO BE SOLVED: To obtain the subject tea beverage for prevention and treatment, etc., of suppression of blood glucose level, diabetes mellitus, hypertension, arteriosclerosis and obesity, etc., having a pH value within a specific acidic range in water solution state and suppressing decomposition of starch to sugar by blending an amylase inhibitor.

SOLUTION: This tea beverage contains an amylase inhibitor. The tea beverage is obtained by dissolving powdery wheat tea, etc., in water at 25°C, adding an amylase inhibitor having an amino acid sequence separated from wheat flour and expressed by the formula so as to be >2000V/ml based on total weight of an aqueous solution of, tea beverage before blending the amylase inhibitor, stirring these components to afford the wheat tea beverage containing amylase inhibitor (having pH6.5), adding at least one kind of acid selected from lactic acid, citric acid, tartaric acid, malic acid, acetic acid, ascorbic acid, etc., as a pH adjuster thereto and controlling pH in a state of water solution to a range of 3.8 to 5.4. The tea beverage suppresses decomposition of starch to sugar and is effective for preventing and treating blood glucose level, diabetes mellitus, hypertension, arteriosclerosis and obesity, etc.

COPYRIGHT: (C) 1997, JPO

WEST

Generate Collection

Print

L2: Entry 27 of 29

File: DWPI

Oct 5, 1993

DERWENT-ACC-NO: 1993-348354

DERWENT-WEEK: 199344

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Liq. compsn. for treating obesity and constipation - contain edible fibre and lactic acid

PATENT-ASSIGNEE:

ASSIGNEE

MIYARISAN SEIBUTSU IGAKU KENKYUSHO KK

CODE

MIYAN

PRIORITY-DATA: 1992JP-0010919 (January 24, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 05255097 A	October 5, 1993		005	A61K035/74

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
JP 05255097A	January 24, 1992	1992JP-0010919	

INT-CL (IPC): A23L 1/30; A23L 1/308; A61K 9/08; A61K 31/70; A61K 31/715; A61K 35/74; A61K 35/78

ABSTRACTED-PUB-NO: JP 05255097A

BASIC-ABSTRACT:

The liq. compsn. contains (1) edible fibre, and (2) lactic acid. Pref. lactic acid is *Clostridium butyricum* NIP 1006; *Clostridium butyricum* NIP 1015; *Clstridium butyricum* NIP 1017; and/or *Clostridium butyricum* Miyairi 588.

The edible fibre is cellulose, hemi-cellulose, ligane, pectin, guar gum, glucomannan, galacto-mannan, carraginin, CMC, arginic acid or its salt and deriv., chitosan, corn bran, wheat bran, yellow pea fibre, orange fibre, chitin, collagen or chondroitin sulphate. The compsn. is forme dinto foods contg. 1 g of edible fibre and 3.3 x 10 power 2 1 x 10 power 11 or lactic acid or into medicine contg. 1 g of fibre, and 3.3 x 10 power 4 - 1 x 10 power 11 of lactic acid.

USE - The liq. compsn. is used for prevention and therapy of constipation and obesity.

In an example, gluco-mannan (30 g) was added to water (1000 ml) and stirred to form juice. Maltitol (100g) orange juice power (50 g), orange flavour (3 ml), vitamin C (10 g), citric acid (1 g), sodium citrate (1 g), lactic acid powder (0.1 g: 1 x 10 power 10), asparagine (2 g) and benzoic acid (0.6 g) were added to the juice to form orange juice. The juice (120 ml) was filled in a glass bottle and air-tightly sealed.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: LIQUID COMPOSITION TREAT OBESITY CONSTIPATION CONTAIN EDIBLE FIBRE

LACTIC ACID

DERWENT-CLASS: B05 D13

CPI-CODES: B04-A07D2; B04-B04A6; B04-C02; B10-C04D; B12-J02; B12-J07; D03-H01T;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

M423 M431 M782 M903 P731 P737 Q211 V400 V404 V752

Chemical Indexing M1 *02*

Fragmentation Code

M423 M431 M782 M903 M904 M910 P731 P737 Q211 V0
V711

Specific Compounds

01852M

Chemical Indexing M1 *03*

Fragmentation Code

J0 J011 J1 J111 J2 J211 K0 L8 L811 L815
L816 L817 L818 L831 L832 M210 M211 M272 M280 M281
M320 M423 M431 M782 M903 M904 P731 P737 Q211 V735

Specific Compounds

17032M

Chemical Indexing M1 *04*

Fragmentation Code

K0 L8 L815 L816 L831 M423 M431 M782 M903 M904
P731 P737 Q211 V735

Specific Compounds

03104M

Chemical Indexing M1 *05*

Fragmentation Code

K0 L8 L814 L815 L831 M423 M431 M782 M903 P731
P737 Q211 V735

Chemical Indexing M1 *06*

Fragmentation Code

K0 K4 K421 K499 L8 L814 L815 L831 M423 M431
M782 M903 P731 P737 Q211 V735

Chemical Indexing M1 *07*

Fragmentation Code

H5 H521 H8 J0 J011 J1 J171 M280 M311 M321
M342 M381 M391 M423 M431 M782 M903 M904 M910 P731
P737 Q211 V0 V713

Specific Compounds

01835M

Chemical Indexing M1 *08*

Fragmentation Code

J0 J011 J1 J111 M423 M431 M630 M782 M903 M904
M910 P731 P737 Q211 V0 V733

Specific Compounds

01866M 07226M

Chemical Indexing M1 *09*

Fragmentation Code

J0 J011 J3 J321 K0 L8 L814 L834 M210 M211
M262 M281 M320 M423 M431 M782 M903 M904 P731 P737
Q211 V735

Specific Compounds

03233M

Chemical Indexing M1 *10*

Fragmentation Code

J0 J011 J1 J111 J321 K0 K4 K421 M423 M431
M782 M903 M904 M910 P731 P737 Q211 V0 V731

Specific Compounds

01875M

Chemical Indexing M1 *12*

Fragmentation Code

M423 M431 M782 M903 P731 P737 Q211 V500 V540

Chemical Indexing M2 *11*

Fragmentation Code

H4 H401 H481 H8 J0 J011 J1 J171 M280 M312
M321 M331 M340 M342 M349 M381 M391 M416 M431 M620
M782 M903 M904 M910 P731 P737 Q211

Specific Compounds

00009M

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0009U; 1835U; 1852U; 1866U; 1875U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1993-154509